PMID- 20727283
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20121002
LR  - 20100823
IS  - 1999-6187 (Electronic)
IS  - 1009-3419 (Linking)
VI  - 11
IP  - 1
DP  - 2008 Feb 20
TI  - [Clinic outcome of gefitinib in sixty-nine elderly patients with lung 
      adenocarcinoma.].
PG  - 137-41
LID - 10.3779/j.issn.1009-3419.2008.01.029 [doi]
AB  - BACKGROUND: To evaluate the efficacy and safety of gefitinib, an orally active 
      epidermal growth factor receptor tyrosine kinase inhibitor(EGFR-TKI), in elderly 
      patients with other types of adenocarcinoma. METHODS: The clinical 
      characteristics, response of treatment and survival were retrospectively reviewed 
      in sixty-nine elderly patients (>=65 years). All these patients received 
      gefitinib 250mg/d in Cancer Institute ( Hospital ), Chinese Aacademy of Medical 
      Sciences until disease progression or toxicities not tolerated by patient. 
      RESULTS: Overall response rate and disease controlled rate (DCR) of gefitinib 
      were 24.6% and 88.4% respectively. The median survival time was 15 months. One 
      year survival was 62.2%. The response rate of gefitinib were significantly higher 
      in patients less than 75-year-old, non-smoker and first-line treatment group than 
      in patients above 75-year-old, smoker and second-line or third-line treatment. 
      Furthermore, the overall survival times were significantly longer in patients of 
      Bronchioloalveolar carcinoma, female and nonsmokers than patients with 
      adenocarcinoma, and male and smokers. Rash and diarrhea were the most common 
      adverse events (AEs) , but usually were mild. CONCLUSIONS: Gefitinib is effective 
      and safe in elderly patients with advanced adenocarcinomas of the lung.
FAU - Wang, Yan
AU  - Wang Y
AD  - Department of Medical Oncology, Cancer Institue (Hospital), Chinese Aacademy of 
      Medical Sciences & Peking Union Medical College, Beijing, 100021, China.
FAU - Zhang, Xiangru
AU  - Zhang X
FAU - Wang, Bin
AU  - Wang B
FAU - Wang, Ziping
AU  - Wang Z
FAU - Chu, Datong
AU  - Chu D
FAU - Sun, Yan
AU  - Sun Y
LA  - chi
PT  - English Abstract
PT  - Journal Article
PL  - China
TA  - Zhongguo Fei Ai Za Zhi
JT  - Zhongguo fei ai za zhi = Chinese journal of lung cancer
JID - 101126433
EDAT- 2008/02/20 00:00
MHDA- 2008/02/20 00:01
CRDT- 2010/08/24 06:00
PHST- 2010/08/24 06:00 [entrez]
PHST- 2008/02/20 00:00 [pubmed]
PHST- 2008/02/20 00:01 [medline]
AID - 10.3779/j.issn.1009-3419.2008.01.029 [doi]
PST - ppublish
SO  - Zhongguo Fei Ai Za Zhi. 2008 Feb 20;11(1):137-41. doi: 
      10.3779/j.issn.1009-3419.2008.01.029.